Home > Press > Harris & Harris Group to Present at 13th Annual Needham Growth Stock Conference on January 13, 2011
 |
Abstract:
The management of Harris & Harris Group, Inc., (NASDAQ: TINY) will present at the 13th Annual Needham Growth Stock Conference scheduled for January 11-13, 2011, at The New York Palace Hotel in New York City.
Harris & Harris Group to Present at 13th Annual Needham Growth Stock Conference on January 13, 2011
New York, NY | Posted on January 6th, 2011Chairman and Chief Executive Officer, Douglas W. Jamison, will present on Thursday, January 13, at 10:40 AM ET in the Holmes I Room. Harris & Harris Group will also meet one-on-one with institutional investors on January 13, 2011. Interested investors should contact the conference organizers at Needham & Company or the Harris & Harris Group's investor relations representative at Lippert/Heilshorn & Associates at
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website www.HHVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
####
About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
For more information, please click here
Copyright © Harris & Harris Group
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Nano-microscope gives first direct observation of the magnetic properties of 2D materials: Discovery means new class of materials and technologies September 18th, 2020
Physicists make electrical nanolasers even smaller September 18th, 2020
Shape matters for light-activated nanocatalysts - Study: Pointed tips on aluminum 'octopods' increase catalytic reactivity September 18th, 2020
Aberrant electronic and structural alterations in pressure tuned perovskite NaOsO3 September 18th, 2020
Investments/IPO's/Splits
180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020
Nanogate: Meeting of creditors on November 4, 2020 September 4th, 2020
Announcements
Nano-microscope gives first direct observation of the magnetic properties of 2D materials: Discovery means new class of materials and technologies September 18th, 2020
Physicists make electrical nanolasers even smaller September 18th, 2020
Shape matters for light-activated nanocatalysts - Study: Pointed tips on aluminum 'octopods' increase catalytic reactivity September 18th, 2020
Aberrant electronic and structural alterations in pressure tuned perovskite NaOsO3 September 18th, 2020
Events/Classes
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment September 16th, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences September 10th, 2020
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020 September 2nd, 2020
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress August 28th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||